AMENDMENT NO. 1 TO THE TENDER OFFER AGREEMENT BETWEEN TXCELL S.A. AND SANGAMO THERAPEUTICS, INC. Dated as of October 1st, 2018Tender Offer Agreement • November 6th, 2018 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances)
To: Sangamo Therapeutics, Inc. Richmond CA 94804 United States of AmericaShare Purchase Agreement • November 6th, 2018 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances)
Reference is made to the Share Purchase Agreement dated July 20, 2018 (the “SPA”), by and between the undersigned shareholders (the “Sellers”) of TxCell S.A., a French société anonyme having its registered office located at Les Cardoulines, allée de la Nertière, Sophia-Antipolis 06560, Valbonne (France), incorporated with the Grasse trade and companies registry under number 435 361 209 R.C.S. (the “Company”) and Sangamo Therapeutics, Inc., a company incorporated in the State of Delaware, whose head office is located at 501 Canal Blvd, Richmond, CA 94804, U.S.A.
